Palisade Bio Stock Performance
| PALI Stock | USD 0.75 0.01 1.32% |
Palisade Bio has a performance score of 3 on a scale of 0 to 100. The company holds a Beta of 0.39, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Palisade Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Palisade Bio is expected to be smaller as well. Palisade Bio right now holds a risk of 4.23%. Please check Palisade Bio treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Palisade Bio will be following its historical price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Palisade Bio are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak essential indicators, Palisade Bio may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Last Split Factor 1:15 | Dividend Date 2019-07-18 | Last Split Date 2024-04-08 |
1 | Palisade Bios AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation ... | 05/01/2025 |
2 | Palisade Bio Expected to Announce Earnings on Monday | 05/05/2025 |
3 | Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative... | 05/06/2025 |
4 | Palisade Bio Receives Buy Rating from Brookline Capital - GuruFocus | 05/14/2025 |
5 | Palisade Bio Reports Positive Phase 1 Results for PALI-2108 PALI Stock News | 05/27/2025 |
6 | Acquisition by Wei Binxian of 388 shares of Palisade Bio subject to Rule 16b-3 | 06/17/2025 |
7 | Acquisition by Wei Binxian of 465 shares of Palisade Bio subject to Rule 16b-3 | 06/20/2025 |
8 | Insider Trading | 07/07/2025 |
9 | Palisade Bio Welcomes Emil Chuang to Board of Directors PALI Stock News | 07/09/2025 |
10 | Is Palisade Bio Inc. a good long term investment - Outstanding capital growth - Jammu Links News | 07/18/2025 |
| Begin Period Cash Flow | 12.5 M |
Palisade Bio Relative Risk vs. Return Landscape
If you would invest 71.00 in Palisade Bio on April 21, 2025 and sell it today you would earn a total of 4.00 from holding Palisade Bio or generate 5.63% return on investment over 90 days. Palisade Bio is currently generating 0.1747% in daily expected returns and assumes 4.2335% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Palisade, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Palisade Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Palisade Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Palisade Bio, and traders can use it to determine the average amount a Palisade Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0413
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PALI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.23 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Palisade Bio is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Palisade Bio by adding it to a well-diversified portfolio.
Palisade Bio Fundamentals Growth
Palisade Stock prices reflect investors' perceptions of the future prospects and financial health of Palisade Bio, and Palisade Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Palisade Stock performance.
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.81 | ||||
| Current Valuation | (3.42 M) | ||||
| Shares Outstanding | 4.8 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 14.03 X | ||||
| EBITDA | (14.86 M) | ||||
| Net Income | (14.44 M) | ||||
| Cash And Equivalents | 5 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 169 K | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 2.59 X | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | (12.19 M) | ||||
| Earnings Per Share | (6.07) X | ||||
| Market Capitalization | 3.75 M | ||||
| Total Asset | 10.88 M | ||||
| Retained Earnings | (135.94 M) | ||||
| Working Capital | 7.26 M | ||||
About Palisade Bio Performance
By evaluating Palisade Bio's fundamental ratios, stakeholders can gain valuable insights into Palisade Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Palisade Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Palisade Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -2.8 K | -3 K | |
| Return On Tangible Assets | (1.33) | (1.39) | |
| Return On Capital Employed | (1.94) | (2.04) | |
| Return On Assets | (1.33) | (1.39) | |
| Return On Equity | (1.93) | (2.02) |
Things to note about Palisade Bio performance evaluation
Checking the ongoing alerts about Palisade Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Palisade Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Palisade Bio has some characteristics of a very speculative penny stock | |
| Palisade Bio had very high historical volatility over the last 90 days | |
| Palisade Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (14.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Palisade Bio currently holds about 5 M in cash with (12.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23. | |
| Latest headline from news.google.com: Is Palisade Bio Inc. a good long term investment - Outstanding capital growth - Jammu Links News |
- Analyzing Palisade Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Palisade Bio's stock is overvalued or undervalued compared to its peers.
- Examining Palisade Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Palisade Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Palisade Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Palisade Bio's stock. These opinions can provide insight into Palisade Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Palisade Stock analysis
When running Palisade Bio's price analysis, check to measure Palisade Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Palisade Bio is operating at the current time. Most of Palisade Bio's value examination focuses on studying past and present price action to predict the probability of Palisade Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Palisade Bio's price. Additionally, you may evaluate how the addition of Palisade Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world |